BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO) Shares Fall as FDA Questions Cancer Drug Survival Trend


8/3/2012 7:46:44 AM

Cambridge, MA-based Aveo Oncology was fired up early this year when it hit the main goal of its pivotal clinical trial with a kidney cancer drug. But today some new questions have emerged about how much benefit its drug is offering to patients, which sent the company’s stock down more than 25 percent. Aveo (NASDAQ: AVEO) said today in its quarterly financial report that the FDA has “expressed concern” about new results from a trial called TIVO-1 which show that 81 percent of patients who were randomly assigned to get Bayer and Onyx Pharmaceuticals’ sorafenib (Nexavar) were alive after one year, compared with 77 percent who got Aveo’s tivozanib. Aveo cautioned that not enough deaths have occurred in the entire trial of 517 patients to make this a final result, and median survival time for the two groups can’t yet be calculated.

Read at Xconomy
Read at Market Watch
Read at Street Insider

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES